IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia

[1]  E. Severance,et al.  Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling , 2016, Schizophrenia Research.

[2]  M. Owen,et al.  Genetic Risk for Schizophrenia: Convergence on Synaptic Pathways Involved in Plasticity , 2015, Biological Psychiatry.

[3]  Jennifer M. Coughlin,et al.  Inflammatory molecular signature associated with infectious agents in psychosis. , 2014, Schizophrenia bulletin.

[4]  N. Roy,et al.  Dietary A1 β-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 β-casein in Wistar rats , 2014, International journal of food sciences and nutrition.

[5]  Peilin Jia,et al.  Transcriptome Sequencing and Genome-wide Association Analyses Reveal Lysosomal Function and Actin Cytoskeleton Remodeling in Schizophrenia and Bipolar Disorder , 2014, Molecular Psychiatry.

[6]  Jia Li,et al.  Idazoxan reduces blood-brain barrier damage during experimental autoimmune encephalomyelitis in mouse. , 2014, European journal of pharmacology.

[7]  K. Blennow,et al.  Blood–cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment , 2014, Psychiatry Research.

[8]  Angie A. Kehagia,et al.  Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation to Symptom Severity, Cognition and Antipsychotic Medication , 2014, PloS one.

[9]  P. Whiteley,et al.  Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders: Behavioural and psychometric measures of dietary response , 2014, Nutritional neuroscience.

[10]  D. Rujescu,et al.  Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. , 2014, Schizophrenia bulletin.

[11]  R. Kapila,et al.  Comparative evaluation of cow β-casein variants (A1/A2) consumption on Th2-mediated inflammatory response in mouse gut , 2014, European Journal of Nutrition.

[12]  M. Osaka,et al.  Oral administration of the milk casein-derived tripeptide Val-Pro-Pro attenuates high-fat diet-induced adipose tissue inflammation in mice , 2014, British Journal of Nutrition.

[13]  B. Prandi,et al.  Qualitative and quantitative determination of peptides related to celiac disease in mixtures derived from different methods of simulated gastrointestinal digestion of wheat products , 2014, Analytical and Bioanalytical Chemistry.

[14]  V. Ellingrod,et al.  Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia , 2014, Journal of psychopharmacology.

[15]  E. Vilella,et al.  Increased serum interleukin-6 levels in early stages of psychosis: Associations with at-risk mental states and the severity of psychotic symptoms , 2014, Psychoneuroendocrinology.

[16]  Károly Mirnics,et al.  Immune System Disturbances in Schizophrenia , 2014, Biological Psychiatry.

[17]  A. Corvin,et al.  Genome-wide Association Studies: Findings at the Major Histocompatibility Complex Locus in Psychosis , 2014, Biological Psychiatry.

[18]  M. Webster,et al.  Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder , 2014, Translational Psychiatry.

[19]  K. McKenzie,et al.  Biomarkers of gluten sensitivity in patients with non-affective psychosis: A meta-analysis , 2014, Schizophrenia Research.

[20]  N. Müller.  Immunology of Schizophrenia , 2014, Neuroimmunomodulation.

[21]  B. Bogerts,et al.  Immune system and glucose metabolism interaction in schizophrenia: A chicken–egg dilemma , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  P. Sham,et al.  Molecular genetic gene–environment studies using candidate genes in schizophrenia: A systematic review , 2013, Schizophrenia Research.

[23]  D. Rujescu,et al.  Elevated gliadin antibody levels in individuals with schizophrenia , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[24]  E. Severance,et al.  Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia , 2013, Schizophrenia Research.

[25]  P. Buckley,et al.  Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses , 2013, Brain, Behavior, and Immunity.

[26]  N. M. Lau,et al.  Markers of Celiac Disease and Gluten Sensitivity in Children with Autism , 2013, PloS one.

[27]  J. Jardin,et al.  Sequential release of milk protein-derived bioactive peptides in the jejunum in healthy humans. , 2013, The American journal of clinical nutrition.

[28]  H. Drexhage,et al.  Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders , 2013, Journal of Neuroimmune Pharmacology.

[29]  E. Meinl,et al.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis , 2013, Nature Reviews Neurology.

[30]  Takahiro A. Kato,et al.  Neuroinflammation in schizophrenia especially focused on the role of microglia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  K. Bechter,et al.  Updating the mild encephalitis hypothesis of schizophrenia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  G. Bu,et al.  TIMP-1 attenuates blood–brain barrier permeability in mice with acute liver failure , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  M. Cairns,et al.  Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia , 2013, Molecular Psychiatry.

[34]  F. Dickerson,et al.  C-reactive protein is elevated in schizophrenia , 2013, Schizophrenia Research.

[35]  D. Cohen,et al.  Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome , 2012, Psychoneuroendocrinology.

[36]  E. Severance,et al.  Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia , 2012, Neurobiology of Disease.

[37]  P. Whiteley,et al.  Gluten- and casein-free dietary intervention for autism spectrum conditions , 2012, Front. Hum. Neurosci..

[38]  J. Sakuma,et al.  Effective surgical intervention for schizophrenia‐like symptoms and low event‐related potentials caused by arachnoid cyst , 2012, Psychiatry and clinical neurosciences.

[39]  D. Kelly,et al.  A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies , 2012, Schizophrenia Research.

[40]  K. Reichelt,et al.  Peptides’ role in autism with emphasis on exorphins , 2012, Microbial ecology in health and disease.

[41]  A. Fasano.  Zonulin, regulation of tight junctions, and autoimmune diseases , 2012, Annals of the New York Academy of Sciences.

[42]  S. Makni,et al.  Spectrum of Autoantibodies in Tunisian Psychiatric Inpatients , 2012, Immunological investigations.

[43]  E. Severance,et al.  Gastrointestinal inflammation and associated immune activation in schizophrenia , 2012, Schizophrenia Research.

[44]  W. Hamilton,et al.  [Increased inflammatory markers]. , 2012, Praxis.

[45]  Qi Xu,et al.  A study of circulating gliadin antibodies in schizophrenia among a Chinese population. , 2012, Schizophrenia bulletin.

[46]  H. Tsai,et al.  Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. , 2012, The British journal of psychiatry : the journal of mental science.

[47]  M. Holtze,et al.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. , 2012, Schizophrenia bulletin.

[48]  R. Yolken,et al.  Toxoplasma gondii and other risk factors for schizophrenia: an update. , 2012, Schizophrenia bulletin.

[49]  B. Leonard,et al.  The metabolic syndrome in schizophrenia: is inflammation a contributing cause? , 2012, Journal of psychopharmacology.

[50]  I. Melle,et al.  Cortical Volume, Surface Area, and Thickness in Schizophrenia and Bipolar Disorder , 2012, Biological Psychiatry.

[51]  R. Murray,et al.  How genes and environmental factors determine the different neurodevelopmental trajectories of schizophrenia and bipolar disorder. , 2012, Schizophrenia bulletin.

[52]  Manuel Desco,et al.  Progressive brain changes in children and adolescents with first-episode psychosis. , 2012, Archives of general psychiatry.

[53]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[54]  D. Cowan,et al.  Association between bovine casein antibody and new onset schizophrenia among US military personnel , 2011, Schizophrenia Research.

[55]  F. Dickerson,et al.  Markers of gluten sensitivity and celiac disease in bipolar disorder. , 2011, Bipolar disorders.

[56]  E. Severance,et al.  Immune activation by casein dietary antigens in bipolar disorder. , 2010, Bipolar disorders.

[57]  F. Dickerson,et al.  Markers of Gluten Sensitivity and Celiac Disease in Recent-Onset Psychosis and Multi-Episode Schizophrenia , 2010, Biological Psychiatry.

[58]  F. Dickerson,et al.  Novel immune response to gluten in individuals with schizophrenia , 2010, Schizophrenia Research.

[59]  E. Severance,et al.  Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia , 2010, Schizophrenia Research.

[60]  P. Whiteley,et al.  The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders , 2010, Nutritional neuroscience.

[61]  D. Fuchs,et al.  Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. , 2010, Journal of psychiatric research.

[62]  V. Nerurkar,et al.  Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. , 2010, Virology.

[63]  R. Drexhage,et al.  The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder , 2010, Expert review of neurotherapeutics.

[64]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[65]  Pall I. Olason,et al.  Common variants conferring risk of schizophrenia , 2009, Nature.

[66]  Jianxin Shi,et al.  Common variants on chromosome 6p22.1 are associated with schizophrenia , 2009, Nature.

[67]  S. Collins,et al.  The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. , 2009, Gastroenterology.

[68]  James M Whedon,et al.  Cerebrospinal fluid stasis and its clinical significance. , 2009, Alternative therapies in health and medicine.

[69]  G. P. Lambert,et al.  Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects. , 2009, Journal of animal science.

[70]  M. Deli,et al.  Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. , 2009, Biochimica et biophysica acta.

[71]  Sefik Alkan,et al.  Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. , 2008, Gastroenterology.

[72]  O. Ekinci,et al.  A left temporal lobe arachnoid cyst in a patient with schizophrenia-like psychosis: A case report , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[73]  R. Yolken,et al.  Are some cases of psychosis caused by microbial agents? A review of the evidence , 2008, Molecular Psychiatry.

[74]  B. Giometto,et al.  Neurological complications of celiac disease and autoimmune mechanisms: A prospective study , 2008, Journal of Neuroimmunology.

[75]  M. Turgut,et al.  Melatonin ameliorates blood–brain barrier permeability, glutathione, and nitric oxide levels in the choroid plexus of the infantile rats with kaolin-induced hydrocephalus , 2007, Brain Research.

[76]  H. Reiber,et al.  Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: Discrimination between microorganism-driven and polyspecific immune response , 2007, Journal of Neuroimmunology.

[77]  M. Fernández.  The metabolic syndrome. , 2007, Nutrition reviews.

[78]  M. Hallett,et al.  Immune Cross-Reactivity in Celiac Disease: Anti-Gliadin Antibodies Bind to Neuronal Synapsin I1 , 2007, The Journal of Immunology.

[79]  Elaine Holmes,et al.  Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia , 2006, PLoS medicine.

[80]  Lin He,et al.  Altered levels of acute phase proteins in the plasma of patients with schizophrenia. , 2006, Analytical chemistry.

[81]  O. Mors,et al.  Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. , 2006, The American journal of psychiatry.

[82]  A. Fasano,et al.  Gliadin Stimulation of Murine Macrophage Inflammatory Gene Expression and Intestinal Permeability Are MyD88-Dependent: Role of the Innate Immune Response in Celiac Disease1 , 2006, The Journal of Immunology.

[83]  G. Hemmings,et al.  A study of the combined effect of the CLDN5 locus and the genes for the phospholipid metabolism pathway in schizophrenia. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[84]  Yan Shen,et al.  Further study of a genetic association between the CLDN5 locus and schizophrenia , 2005, Schizophrenia Research.

[85]  Sheng-He Huang,et al.  Blood-brain barrier drug discovery for central nervous system infections. , 2005, Current drug targets. Infectious disorders.

[86]  Y. Shen,et al.  The CLDN5 locus may be involved in the vulnerability to schizophrenia , 2004, European Psychiatry.

[87]  J. Green,et al.  Immune Response to Dietary Proteins, Gliadin and Cerebellar Peptides in Children with Autism , 2004, Nutritional neuroscience.

[88]  H. Kühn,et al.  Intrathecal synthesis of autoantibodies against tissue transglutaminase. , 2004, Journal of autoimmunity.

[89]  O. Mors,et al.  Coeliac disease and schizophrenia: population based case control study with linkage of Danish national registers , 2004, BMJ : British Medical Journal.

[90]  R. Yolken,et al.  Antibodies to infectious agents in individuals with recent onset schizophrenia , 2004, European Archives of Psychiatry and Clinical Neuroscience.

[91]  J. Mazziotta,et al.  Increases in regional subarachnoid CSF without apparent cortical gray matter deficits in schizophrenia: modulating effects of sex and age. , 2003, The American journal of psychiatry.

[92]  S. Virgiliis,et al.  Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function , 2003, Gut.

[93]  J. Dichgans,et al.  The humoral response in the pathogenesis of gluten ataxia , 2002, Neurology.

[94]  G. Davies-Jones,et al.  The humoral response in the pathogenesis of gluten ataxia , 2002, Neurology.

[95]  R. Pioli,et al.  Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16 , 2001, Psychiatry Research.

[96]  M. Skalej,et al.  Sporadic cerebellar ataxia associated with gluten sensitivity. , 2001, Brain : a journal of neurology.

[97]  Hansotto Reiber,et al.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs , 2001, Journal of the Neurological Sciences.

[98]  M. Tsuang.  Schizophrenia: genes and environment , 2000, Biological Psychiatry.

[99]  J. Peter,et al.  Autoantibodies in Neurodegenerative Diseases: Antigen-Specific Frequencies and Intrathecal Analysis , 1998, Neurobiology of Aging.

[100]  D. Turnbull,et al.  CSF antigliadin antibodies and the Ramsay Hunt syndrome , 1997, Neurology.

[101]  K. Reichelt,et al.  Specific IgA antibody increases in schizophrenia , 1995, Biological Psychiatry.

[102]  H. Reiber.  Flow rate of cerebrospinal fluid (CSF) — A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases , 1994, Journal of the Neurological Sciences.

[103]  R. Sandyk.  Choroid plexus calcification as a possible marker of hallucinations in schizophrenia. , 1993, The International journal of neuroscience.

[104]  K. Reichelt.  Peptides in schizophrenia , 1991, Biological Psychiatry.

[105]  L. Terenius,et al.  CSF levels of receptor-active endorphins in schizophrenic patients: Correlations with symptomalogy and monoamine metabolites , 1986, Psychiatry Research.

[106]  D. Weinberger,et al.  Abnormal cerebrospinal fluid protein indices in schizophrenia , 1985, Biological Psychiatry.

[107]  K. Reichelt,et al.  Urinary peptides in schizophrenia and depression , 1985 .

[108]  L. Terenius,et al.  CSF and plasma beta-casomorphin-like opioid peptides in postpartum psychosis. , 1984, The American journal of psychiatry.

[109]  Dohan Fc.  Schizophrenia, celiac disease, gluten antibodies, and the importance of beta. , 1981 .

[110]  Rudin Do.  The choroid plexus and system disease in mental illness. III. The exogenous peptide hypothesis of mental illness. , 1981 .

[111]  Rudin Do.  The choroid plexus and system disease in mental illness. II. Systemic lupus erythematosus: a combined transport dysfunction model for schizophrenia. , 1981 .

[112]  Rudin Do.  The choroid plexus and system disease in mental illness. I. A new brain attack mechanism via the second blood--brain barrier. , 1980 .

[113]  F. Dohan.  SCHIZOPHRENIA AND NEUROACTIVE PEPTIDES FROM FOOD , 1979, The Lancet.

[114]  K. Felgenhauer,et al.  Serum-CSF protein gradients, the blood-CSF barrier and the local immune response , 1978, Journal of Neurology.

[115]  K. Felgenhauer,et al.  Serum-CSF protein gradients, the blood-CSF barrier and the local immune response , 1978, Journal of Neurology.

[116]  S. Ohman,et al.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. , 1977, Scandinavian journal of clinical and laboratory investigation.

[117]  R. Ferguson,et al.  LYMPHOID CELLS IN JEJUNAL MUCOSA , 1975, The Lancet.

[118]  F. Dohan,et al.  Relapsed schizophrenics: earlier discharge from the hospital after cereal-free, milk-free diet. , 1973, The American journal of psychiatry.

[119]  F. Dohan,et al.  Relapsed Schizophrenics: More Rapid Improvement on a Milk- and Cereal-free Diet , 1969, British Journal of Psychiatry.

[120]  F. Dohan.  WARTIME CHANGES IN HOSPITAL ADMISSIONS FOR SCHIZOPHRENIA , 1966 .

[121]  I. Marinescu,et al.  Choroid plexus calcification: clinical, neuroimaging and histopathological correlations in schizophrenia. , 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[122]  O. Howes,et al.  Inflammation: its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics , 2013, Psychopharmacology.

[123]  M. Schwarz,et al.  Inflammation in schizophrenia. , 2012, Advances in protein chemistry and structural biology.

[124]  D. Kelly,et al.  Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. , 2011, Schizophrenia bulletin.

[125]  W. Nolen,et al.  Immune and neuroimmune alterations in mood disorders and schizophrenia. , 2011, International review of neurobiology.

[126]  S. Kamiński,et al.  Polymorphism of bovine beta-casein and its potential effect on human health , 2010, Journal of Applied Genetics.

[127]  L. Mundt.  Comprar Graff's Textbook of Routine of Urinalysis and Body Fluids | Lillian Mundt | 9781582558752 | Lippincott Williams & Wilkins , 2010 .

[128]  H. Zhu,et al.  Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene , 2005, Amino Acids.

[129]  R. Suddath,et al.  Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia , 2005, Journal of Neural Transmission / General Section JNT.

[130]  J. Kornhuber,et al.  Blood-cerebrospinal fluid barrier in schizophrenic patients , 2004, European archives of psychiatry and neurological sciences.

[131]  J. Söderholm,et al.  Stress and gastrointestinal tract. II. Stress and intestinal barrier function. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[132]  G. Goldstein,et al.  Blood—Cerebrospinal Fluid Barrier , 1999 .

[133]  F. Dohan.  Genetic hypothesis of idiopathic schizophrenia: its exorphin connection. , 1988, Schizophrenia bulletin.

[134]  D. O. Rudin.  The choroid plexus and system disease in mental illness. II. Systemic lupus erythematosus: a combined transport dysfunction model for schizophrenia. , 1981, Biological psychiatry.

[135]  D. O. Rudin.  The choroid plexus and system disease in mental illness. III. The exogenous peptide hypothesis of mental illness. , 1981, Biological psychiatry.

[136]  K. Reichelt,et al.  Biologically active peptide-containing fractions in schizophrenia and childhood autism. , 1981, Advances in biochemical psychopharmacology.

[137]  Noel R. Rose.  Autoimmune diseases. , 1981, Scientific American.

[138]  Dohan Fc.  Hypothesis: genes and neuroactive peptides from food as cause of schizophrenia. , 1980 .

[139]  D. O. Rudin.  The choroid plexus and system disease in mental illness. I. A new brain attack mechanism via the second blood--brain barrier. , 1980, Biological psychiatry.

[140]  F. Dohan.  Wheat "consumption" and hospital admissions for schizophrenia during World War II. A preliminary report. , 1966, The American journal of clinical nutrition.